J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (5)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fang, L.
Right arrow Articles by Sun, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fang, L.
Right arrow Articles by Sun, D.

BIOLOGICS

Population Pharmacokinetics of Humanized Monoclonal Antibody HuCC49{triangleup}CH2 and Murine Antibody CC49 in Colorectal Cancer Patients

Lanyan Fang, MS, Nicholas H. G. Holford, MB, ChB, George Hinkle, MS, Xianhua Cao, MS, Jim J. Xiao, PhD, Mark Bloomston, MD, Seth Gibbs, BS, Osama Habib Al Saif, MD, James T. Dalton, PhD, Kenneth K. Chan, PhD, Jeffery Schlom, PhD, Edward W. Martin, Jr, MD and Duxin Sun, PhD

From the Division of Pharmaceutics, College of Pharmacy (Ms Fang, Mr Hinkle, Mr Cao, Mr Gibbs, Dr Dalton, Dr Chan, Dr Sun); Surgical Oncology, James Cancer Hospital and Solove Research Institute (Dr Bloomston, Dr Saif, Dr Martin); The Ohio State University, Columbus, Ohio; the Department of Pharmacology and Clinical Pharmacology, University of Auckland, New Zealand (Dr Holford); Pharmacokinetics and Drug Metabolism, Amgen Inc, Thousand Oaks, California (Dr Xiao); and the Laboratory of Tumor Immunology and Biology, National Institute of Health, Bethesda, Maryland (Dr Schlom).

To predict the optimal time for surgery after antibody administration, the population pharmacokinetics of 125I-HuCC49{triangleup}CH2 and 125I-CC49 were characterized in 55 patients with colorectal cancers. A 2-compartment linear model was used to fit the pharmacokinetic data. Model stability and performance were assessed using a visual predictive check procedure. Different clinical trial designs were evaluated by simulation in combination with Bayesian estimation method to predict the optimal time for surgery. The results showed that HuCC49{triangleup}CH2 had 65% faster clearance from blood circulation and 24% shorter mean residence time than CC49. Population pharmacokinetic analysis identified body weight as the only covariate to explain between-subject variability in clearance, intercompartmental flow rate, and volume of distribution. Model predictions indicated a wide interval for the optimal time of surgery, suggesting that it would be beneficial to individualize the time of surgery for each patient by measurement of antibody disposition. Clinical trial designs with at least 3 measurements of antibody disposition were found to be better than an empirical direct observation method for the optimal prediction of surgery time.

Key Words: Population pharmacokinetics • Bayesian estimation • RIGS

Address for reprints: Address for correspondence: Duxin Sun, PhD, Division of Pharmaceutics, College of Pharmacy, The Ohio State University, 232 Parks Hall, 500 West 12th Avenue, Columbus, OH 43210.




This article has been cited by other articles:


Home page
 Drug Metab. Dispos.Home page
L. Fang and D. Sun
Predictive Physiologically Based Pharmacokinetic Model for Antibody-Directed Enzyme Prodrug Therapy
Drug Metab. Dispos., June 1, 2008; 36(6): 1153 - 1165.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the American College of Clinical Pharmacology